This Monday, the Food and Drug Administration (FDA, for its acronym in English) announced that approved a drug to prevent respiratory illness caused by respiratory syncytial virus (RSV) in infants and young children.
the drug, made by Sanofi and AstraZeneca, It will help prevention among babies or children who face the first circulation of the virus, and also those up to 2 years of age who are still vulnerable to the disease.
In most of the country, Virus circulation is seasonal, typically beginning in the fall and peaking in the winter. The disease is spread from person to person through contact with someone who is infected.
“RSV can cause severe illness in infants and some children, and results in a large number of visits each year to emergency rooms and physicians’ offices,” said John Falrey, director of the FDA’s Office of Infectious Diseases.
“Today’s approval addresses a great need for products that help reduce the impact of RSV on children, families, and the health care system,” he added.
The virus causes an acute respiratory infection in people of all ages. And while most infants and children experience mild, cold-like symptoms, some infants, especially on their first infection, develop illnesses such as pneumonia and bronchitis.
According to the American Academy of Pediatrics, approximately 1-3% of children under 12 months of age in the United States are hospitalized each year due to RSV.
The FDA explained that beyfortus is a monoclonal antibody with activity against RSV.
A dose given by intramuscular injection before or during the start of the virulence season may provide protection during the RSV season.
According to the Centers for Disease Control and Prevention (CDC) 58,000 to 80,000 children under 5 years of age are hospitalized each year due to infection with this virus.
Keep reading:
* The UN estimates that AIDS could be eradicated by 2030
* This is what is known about the Guillain-Barré syndrome outbreak that keeps Peru in a health emergency
*
2023-07-18 02:50:11
#FDA #Approves #RSV #Drug #Infants #Children #Journal
